Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (NCT03020030)
🩺 Plain-English Summary (8th-Grade Level)
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells. ALL is always fatal if it is not treated. With current treatments, most children and adolescents with this disease will be cured. The standard treatment for ALL involves about 2 years of chemotherapy. The drugs that are used, and the doses of the drugs, are similar but not identical for all children and adolescents with ALL. Some children and adolescents receive stronger treatment, especially during the first several months. A number of factors are used to decide how strong the treatment should be to give the best chance for cure. These factors are called "risk factors". This trial is studying the use of a new, updated set of risk factors to decide how strong the treatment will be. The study also will test a new way of dosing a chemotherapy drug called pegaspargase (which is part of the standard treatment for ALL) based on checking levels of the drug in the blood and adjusting the dose based on the levels.
Who can join: Review the eligibility criteria below.
Location: Boston Children's Hospital — Boston, Massachusetts
Age range: 1 Year to 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Boston Children's Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Roswell Park Cancer Institute — Buffalo, New York
- Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Hasbro Children's Hospital / Rhode Island Hospital — Providence, Rhode Island
- Hospital Sainte Justine, University of Montreal — Montreal, Quebec
- Centre Hospitalier U. de Quebec — Québec, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Lymphoblastic Leukemia, Pediatric
- Low GI Diet in Children and Adolescents With ALL — Hartford, Connecticut
- Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 — Buffalo, New York
- Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia — Washington D.C., District of Columbia
Explore by condition: All Acute Lymphoblastic Leukemia, Pediatric clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.